Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

21 Mar 2018

Britain's use of copycat biotech drugs takes off while U.S. lags

LONDON Cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds ($113 million) a year, experts said on Wednesday.

21 Mar 2018

GlaxoSmithKline prescribes commercial reboot for pharma division

LONDON In January, GlaxoSmithKline's new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent.

07 Mar 2018

Primitive art: Neanderthals were Europe's first painters

LONDON The world's oldest known cave paintings were made by Neanderthals, not modern humans, suggesting our extinct cousins were far from being uncultured brutes. | Video

01 Mar 2018

Big pharma, big data: why drugmakers want your health records

LONDON Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world.

28 Feb 2018

Europe follows FDA with plans to help early Alzheimer's drugs

LONDON European regulators are following in the footsteps of the U.S. Food and Drug Administration with plans to help pharmaceutical companies win approval for novel Alzheimer's drugs that treat the earliest stages of the memory-robbing disease.

28 Feb 2018

AstraZeneca spins off autoimmune drugs into new biotech company

LONDON AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.

22 Feb 2018

Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

21 Feb 2018

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.

19 Feb 2018

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

15 Feb 2018

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.


  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 33,136.18 + 139.42 +0.42%
Nikkei 21,380.97 -99.93 -0.47%
Hang Seng 31,414.52 -135.41 -0.43%
EUR/INR 80.420 +0.77%
USD/INR 65.170 -0.05%
GBP/INR 92.118 +0.94%
Gold 1,328.80 +17.70 +1.35%
Oil 65.48 +1.94 +3.05%
Corn 375.00 +0.50 +0.13%